Biogen Tells High Court Interference Appeals Are Not Limited To Federal Circuit
(March 3, 2016, 3:45 PM EST) -- WASHINGTON, D.C. — The Leahy-Smith America Invents Act (AIA) allows district court review of patent interferences before Sept. 16, 2012, Biogen MA Inc. argues to the U.S. Supreme Court in a Feb. 23 brief, further asserting that the Federal Circuit U.S. Court of Appeals does not have exclusive jurisdiction over appeals (Biogen MA, Inc. v. Japanese Foundation for Cancer Research and Bayer Pharma AG, No. 15-607, U.S. Sup.).